Pharmaceuticals

iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax

* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...

2023-01-26 10:34 1363

Singleron launches single cell eQTL analysis as part of their sequencing service

A new bioinformatic pipeline to investigate single cell eQTL analysis is now offered in the sequencing service from Singleron Biotechnologies. COLOGNE, Germany, Jan. 25, 2023 /PRNewswire/ -- Bioinformatic experts at Singleron Biotechnologies , a leader in single cell sequ...

2023-01-25 19:00 1448

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thata poster presentation highlighting the Phase 1 preliminary result...

2023-01-20 21:50 3547

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced that the U.S. Food...

2023-01-20 18:00 2625

$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

SAN DIEGO, Jan. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in t...

2023-01-20 09:50 1593

NEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTS

* QINLOCK® (ripretinib) now Medsafe approved for GIST patients in NZ * QINLOCK now being considered by PHARMAC for reimbursement * Data from the INVICTUS Phase 3 study shows QINLOCK reduces risk of disease progression or death by 85%1, 2 SINGAPORE and AUCKLAND, New Zealand, Jan. 19, 2023 /PR...

2023-01-20 02:00 1835

Tigermed Completes Acquisition of Marti Farm

HANGZHOU, China and ZAGREB, Croatia, Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of Marti F...

2023-01-19 14:59 3289

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

SUZHOU, China, and ROCKVILLE, MD, Jan. 18, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), today an...

2023-01-19 11:45 1502

Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM

CHENGDU, China, Jan. 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (Stock Code: 02162 HK) is pleased to announce that the latest data from the Phase Ia dose-escalation trial of CMG901 (Claudin 18.2 antibody drug conjugate), a novel drug candidate, for advanced solid tumors will be presented as...

2023-01-18 09:52 1296

IASO Bio Raises Nearly $75 Million in Series C1 Funding

Approaches Commercialization of First Product NANJING and SHANGHAI, China and SAN JOSE, Calif., Jan. 17, 2023 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody p...

2023-01-18 08:00 1379

Asieris Appoints Dr. Linda Wu as Chief Development Officer

SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced thatLinda Wu, Ph.D. will join Asieris...

2023-01-18 07:00 1545

Tanso Biosciences Expands Its Line-up with 250 Mouse GPCRs

TOKYO, Jan. 17, 2023 /PRNewswire/ -- Tanso Biosciences, a leading provider of functional assays for G-protein-coupled receptors (GPCRs), is thrilled to announce a major expansion of its assay platform. Building upon its already extensive coverage of 300 human GPCRs, Tanso Biosciences has added 25...

2023-01-18 00:00 1550

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments ofSteffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO). Dr. Heeger has held senior oncology clinical developme...

2023-01-17 10:00 1311

FDA Accepts GMP Plasmid DMF of OBiO Technology

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and manufacturing organization (CDMO), recently announced that the United States Food and Drug Administ...

2023-01-17 08:00 1343

CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, andHuadong Medicine ( Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co....

2023-01-16 18:00 1511

DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS

-  Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. -  Debiopharm is developing Debio 4126, a novel 3-month ext...

2023-01-12 17:00 1464

Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future

* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...

2023-01-11 08:01 1498

Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations

SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertinib for the treatment of advanced NSCLC with EGFR exon20ins...

2023-01-10 17:03 1321

SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'

SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...

2023-01-10 07:00 1195

SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships

* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...

2023-01-10 07:00 1141
12345 ... 84